CFDA approves Roche's Actemra for sJIA
By Pearl Liu
Staff Writer
Staff Writer
HONG KONG – The CFDA approved the Roche Group's Actemra, which targets systemic juvenile idiopathic arthritis (sJIA).
HONG KONG – The CFDA approved the Roche Group's Actemra, which targets systemic juvenile idiopathic arthritis (sJIA).